Cargando…
Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells
We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009744/ https://www.ncbi.nlm.nih.gov/pubmed/24799968 http://dx.doi.org/10.2174/1874357901408010001 |
_version_ | 1782479795028754432 |
---|---|
author | Bobardt, Michael Chatterji, Udayan Lim, Precious Gawlik, Katarzyna Gallay, Philippe |
author_facet | Bobardt, Michael Chatterji, Udayan Lim, Precious Gawlik, Katarzyna Gallay, Philippe |
author_sort | Bobardt, Michael |
collection | PubMed |
description | We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the possibility of a relationship between CypA, NS5A and PKR in the IFN response to HCV. HCV-infected cells treated with CypI, DAAs or IFN were analyzed for the expression and activation of various components of the innate response. We found that CypI (cyclosporine A, alisporivir, NIM811 and sanglifehrins), drastically prevented the activation/phosphorylation, but not the expression of IFN-induced PKR in HCV-infected cells. CypI had no effect on the expression or phosphorylation of other components of the innate response such as eiF2, NF-kB, IRF3, IRF9, STAT1 and STAT2, suggesting a specific effect on PKR. No significant activation of IFN-induced PKR was observed in the absence of HCV. Importantly, we found that several classes of DAAs such as NS3/4A protease, NS5B polymerase and NS5A inhibitors also prevented PKR activation. Furthermore, we found that PKR activation by the dsRNA mimic poly I:C cannot be prevented by CypI or DAAs. Our findings suggest that CypI do not have a unique effect on PKR activation, but rather the suppression of HCV replication by any anti-HCV inhibitor, abrogates PKR activation induced by IFN. Moreover, they suggest that the accumulation of dsRNA intermediates allows HCV to exploit the activation of PKR to counteract the IFN response. |
format | Online Article Text |
id | pubmed-4009744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-40097442014-05-05 Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells Bobardt, Michael Chatterji, Udayan Lim, Precious Gawlik, Katarzyna Gallay, Philippe Open Virol J Article We and others demonstrated that the contact between NS5A and the host factor CypA is critical for HCV replication. CypI, by disrupting NS5A-CypA complexes, block HCV replication both in vitro and in patients. Since NS5A also binds to PKR, a central component of the IFN response, we investigated the possibility of a relationship between CypA, NS5A and PKR in the IFN response to HCV. HCV-infected cells treated with CypI, DAAs or IFN were analyzed for the expression and activation of various components of the innate response. We found that CypI (cyclosporine A, alisporivir, NIM811 and sanglifehrins), drastically prevented the activation/phosphorylation, but not the expression of IFN-induced PKR in HCV-infected cells. CypI had no effect on the expression or phosphorylation of other components of the innate response such as eiF2, NF-kB, IRF3, IRF9, STAT1 and STAT2, suggesting a specific effect on PKR. No significant activation of IFN-induced PKR was observed in the absence of HCV. Importantly, we found that several classes of DAAs such as NS3/4A protease, NS5B polymerase and NS5A inhibitors also prevented PKR activation. Furthermore, we found that PKR activation by the dsRNA mimic poly I:C cannot be prevented by CypI or DAAs. Our findings suggest that CypI do not have a unique effect on PKR activation, but rather the suppression of HCV replication by any anti-HCV inhibitor, abrogates PKR activation induced by IFN. Moreover, they suggest that the accumulation of dsRNA intermediates allows HCV to exploit the activation of PKR to counteract the IFN response. Bentham Open 2014-03-07 /pmc/articles/PMC4009744/ /pubmed/24799968 http://dx.doi.org/10.2174/1874357901408010001 Text en © Bobardt et al.; Licensee Bentham Open. http: //creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Bobardt, Michael Chatterji, Udayan Lim, Precious Gawlik, Katarzyna Gallay, Philippe Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title_full | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title_fullStr | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title_full_unstemmed | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title_short | Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells |
title_sort | both cyclophilin inhibitors and direct-acting antivirals prevent pkr activation in hcv-infected cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009744/ https://www.ncbi.nlm.nih.gov/pubmed/24799968 http://dx.doi.org/10.2174/1874357901408010001 |
work_keys_str_mv | AT bobardtmichael bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells AT chatterjiudayan bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells AT limprecious bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells AT gawlikkatarzyna bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells AT gallayphilippe bothcyclophilininhibitorsanddirectactingantiviralspreventpkractivationinhcvinfectedcells |